Access the full text.
Sign up today, get DeepDyve free for 14 days.
Camille Abboud, Ellin Berman, Adam Cohen, J. Cortes, D. DeAngelo, M. Deininger, Steven Devine, B. Druker, Amir Fathi, E. Jabbour, M. Jagasia, H. Kantarjian, Jean Khoury, Pierre Laneuville, Richard Larson, Jeffrey Lipton, Joseph Moore, T. Mughal, Susan O'Brien, J. Pinilla-Ibarz, A. Quintás-Cardama, J. Radich, Vishnu Reddy, Charles Schiffer, Neil Shah, P. Shami, Richard Silver, David Snyder, Richard Stone, Moshe Talpaz, A. Tefferi, R. Etten, M. Wetzler, E. Abruzzese, Jane Apperley, Massimo Breccia, Jenny Byrne, Francisco Cervantes, E. Chelysheva, Richard Clark, H. Lavallade, Iryna Dyagil, C. Gambacorti-Passerini, J. Goldman, İ. Haznedaroğlu, H. Hjorth-Hansen, T. Holyoake, B. Huntly, P. Coutre, E. Lomaia, F. Mahon, David Marin-Costa, Giovanni Martinelli, Jiří Mayer, D. Milojkovic, Eduardo Olavarria, K. Porkka, Johan Richter, Philippe Rousselot, G. Saglio, G. Saydam, J. Stentoft, A. Turkina, Paolo Vigneri, A. Zaritskey, Alvaro Aguayo, M. Ayala, Israel Bendit, R. Bengió, Carlos Best, Eduardo Bullorsky, E. Cervera, Carmino DeSouza, E. Fanilla, D. Gómez-Almaguer, N. Hamerschlak, Jose Lopez, A. Magariños, L. Meillon, J. Milone, B. Moiraghi, R. Pasquini, C. Pavlovsky, G. Ruiz-Argüelles, Nelson Spector, Christopher Arthur, P. Browett, Andrew Grigg, Jianda Hu, Xiao-Jun Huang, T. Hughes, Qian Jiang, S. Jootar, Dong-Wook Kim, Hemant Malhotra, Pankaj Malhotra, I. Matsumura, Junia Melo, K. Ohnishi, Ryuzo Ohno, Tapan Saikia, A. Schwarer, N. Takahashi, Constantine Tam, Tetsuzo Tauchi, Kensuke Usuki, Jianxiang Wang, Fawzi Abdel-Rahman, M. Aljurf, A. Bazarbachi, D. Yehuda, N. Chaudhri, M. Durosinmi, Hossam Kamel, Vernon Louw, B. Matti, A. Nagler, Pia Raanani, Ziad Salem (2013)
The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts.Blood, 121 22
A. Leunis, H. Blommestein, P. Huijgens, N. Blijlevens, M. Jongen‐Lavrencic, C. Groot (2013)
The costs of initial treatment for patients with acute myeloid leukemia in the Netherlands.Leukemia research, 37 3
SR Solomon, RH Matthews, AM Barreras, A. Bashey, KL Manion, K. McNatt, D. Speckhart, DG Connaghan, LE Morris, HK Holland (2010)
Outpatient myeloablative allo-SCT: a comprehensive approach yields decreased hospital utilization and low TRMBone Marrow Transplantation, 45
M. Othus, H. Kantarjian, S. Petersdorf, F. Ravandi, J. Godwin, J. Cortes, S. Pierce, H. Erba, S. Faderl, F. Appelbaum, E. Estey (2014)
Declining rates of treatment-related mortality in patients with newly diagnosed AML given ‘intense’ induction regimens: a report from SWOG and MD AndersonLeukemia, 28
D. Himmelstein, S. Woolhandler (2012)
Cost control in a parallel universe: Medicare spending in the United States and Canada.Archives of internal medicine, 172 22
Tara Graff, Arun Singavi, William Schmidt, Daniel Eastwood, W. Drobyski, M. Horowitz, Jeanne Palmer, M. Pasquini, Douglas Rizzo, W. Saber, P. Hari, T. Fenske (2015)
Safety of outpatient autologous hematopoietic cell transplantation for multiple myeloma and lymphomaBone Marrow Transplantation, 50
A. Freifeld, E. Bow, K. Sepkowitz, M. Boeckh, J. Ito, C. Mullen, I. Raad, K. Rolston, Jo-Anne Young, J. Wingard (2011)
Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 52 4
L Adès, R Itzykson, P Fenaux (2014)
Myelodysplastic syndromes., 383
T. Møller, O. Nielsen, Pernille Welinder, Anne Dünweber, Maiken Hjerming, C. Moser, L. Kjeldsen (2010)
Safe and feasible outpatient treatment following induction and consolidation chemotherapy for patients with acute leukaemiaEuropean Journal of Haematology, 84
R. Cook, B. Dickens, M. Fathalla (2003)
World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.The Journal of the American College of Dentists, 81 3
C. Gutiérrez-Aguirre, G. Ruiz-Argüelles, O. Cantú-Rodríguez, Ó. González-Llano, J. Jaime-Pérez, F. García‐Rodríguez, A. López-Otero, J. Herrera-Garza, D. Gómez-Almaguer (2010)
Outpatient reduced-intensity allogeneic stem cell transplantation for patients with refractory or relapsed lymphomas compared with autologous stem cell transplantation using a simplified methodAnnals of Hematology, 89
V. Nerich, B. Lioure, M. Rave, C. Récher, A. Pigneux, B. Witz, M. Escoffre‐Barbe, M. Moles, E. Jourdan, J. Cahn, M. Woronoff‐Lemsi (2011)
Induction-related cost of patients with acute myeloid leukaemia in FranceInternational Journal of Clinical Pharmacy, 33
T. Halim, K. Song, M. Barnett, D. Forrest, D. Hogge, S. Nantel, T. Nevill, J. Shepherd, C. Smith, H. Sutherland, C. Toze, J. Lavoie (2007)
Positive impact of selective outpatient management of high-risk acute myelogenous leukemia on the incidence of septicemia.Annals of oncology : official journal of the European Society for Medical Oncology, 18 7
Jaime Preussler, Ellen Denzen, N. Majhail (2012)
Costs and cost-effectiveness of hematopoietic cell transplantation.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 18 11
R. Walter, Stephanie Lee, Kelda Gardner, X. Chai, K. Shannon‐Dorcy, F. Appelbaum, E. Estey (2011)
Outpatient management following intensive induction chemotherapy for myelodysplastic syndromes and acute myeloid leukemia: a pilot studyHaematologica, 96
F. Ferrara, C. Schiffer (2013)
Acute myeloid leukaemia in adultsThe Lancet, 381
B. Meisenberg, W. Miller, R. McMillan, M. Callaghan, Christine Sloan, T. Brehm, M. Kosty, J. Kroener, R. Longmire, A. Saven, L. Piro (1997)
Outpatient high-dose chemotherapy with autologous stem-cell rescue for hematologic and nonhematologic malignancies.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 15 1
M. Apreza-Molina, D. Aleman-Hoey, D. Gómez-Almaguer, A. Marín‐López, Leopoldo Mercado‐Díaz (1995)
Outpatient supportive therapy after induction to remission therapy in adult acute myelogenous leukaemia (AML) is feasible: a multicentre studyEuropean Journal of Haematology, 54
Barry Meisenberg, Barry Meisenberg, K. Ferran, K. Ferran, Kathryn Hollenbach, Kathryn Hollenbach, T. Brehm, J. Jollon, Lawrence Piro (1998)
Reduced charges and costs associated with outpatient autologous stem cell transplantationBone Marrow Transplantation, 21
S. Gillis, E. Dann, D. Rund (1996)
Selective discharge of patients with acute myeloid leukemia during chemotherapy‐induced neutropeniaAmerican Journal of Hematology, 51
T. Fojo, S. Mailankody, A. Lo (2014)
Unintended consequences of expensive cancer therapeutics—the pursuit of marginal indications and a me-too mentality that stifles innovation and creativity: the John Conley Lecture.JAMA otolaryngology-- head & neck surgery, 140 12
Christiane, Druml, Wolzt, Pleiner (2000)
World Medical Association Declaration of HelsinkiInternational Journal of Pharmaceutical Medicine, 14
M. Martino, M. Montanari, B. Bruno, G. Console, G. Irrera, G. Messina, M. Offidani, I. Scortechini, T. Moscato, R. Fedele, G. Milone, L. Castagna, A. Olivieri (2012)
Autologous hematopoietic progenitor cell transplantation for multiple myeloma through an outpatient programExpert Opinion on Biological Therapy, 12
R. Walter, Lenise Taylor, Kelda Gardner, K. Dorcy, J. Vaughn, E. Estey (2013)
Outpatient management following intensive induction or salvage chemotherapy for acute myeloid leukemia.Clinical advances in hematology & oncology : H&O, 11 9
P. Stiff, P. Mumby, L. Miler, T. Rodriguez, M. Parthswarthy, K. Kiley, N. Porter, R. Batiste, S. Wojtowitz, S. Lichtenstein, M. Fox-Geiman, A. Toor (2006)
Autologous hematopoietic stem cell transplants that utilize total body irradiation can safely be carried out entirely on an outpatient basisBone Marrow Transplantation, 38
M. Savoie, T. Nevil, K. Song, D. Forrest, D. Hogge, S. Nantel, J. Shepherd, Clayton Smith, H. Sutherland, C. Toze, J. Lavoie (2006)
Shifting to outpatient management of acute myeloid leukemia: a prospective experience.Annals of oncology : official journal of the European Society for Medical Oncology, 17 5
P. Campbell, P. Walker, S. Avery, S. Patil, D. Curtis, A. Schwarer, A. Wei, A. Kalff, J. Muirhead, A. Spencer (2014)
Safe and effective use of outpatient non-myeloablative allogeneic stem cell transplantation for myelomaBlood Cancer Journal, 4
S. Mcdiarmid, B. Hutton, H. Atkins, I. Bence‐Bruckler, C. Bredeson, E. Sabri, L. Huebsch (2010)
Performing allogeneic and autologous hematopoietic SCT in the outpatient setting: effects on infectious complications and early transplant outcomesBone Marrow Transplantation, 45
A. Holbro, I. Ahmad, S. Cohen, J. Roy, S. Lachance, M. Chagnon, R. LeBlanc, L. Bernard, L. Busque, D. Roy, G. Sauvageau, T. Kiss (2013)
Safety and cost-effectiveness of outpatient autologous stem cell transplantation in patients with multiple myeloma.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 19 4
A. Stalfelt, H. Brodin (1994)
Costs over time in conventional treatment of acute myeloid leukaemia: A study exploring changes in treatment strategies over two decadesJournal of Internal Medicine, 236
A. Redaelli, M. Botteman, J. Stephens, Suzanne Brandt, C. Pashos (2004)
Economic burden of acute myeloid leukemia: a literature review.Cancer treatment reviews, 30 3
Benjamin Craig, D. Rollison, A. List, C. Cogle (2011)
Diagnostic testing, treatment, cost of care, and survival among registered and non-registered patients with myelodysplastic syndromes.Leukemia research, 35 11
D. Allan, R. Buckstein, K. Imrie (2001)
Outpatient Supportive Care Following Chemotherapy for Acute Myeloblastic LeukemiaLeukemia & Lymphoma, 42
D. Himmelstein, D. Thorne, E. Warren, S. Woolhandler (2009)
Medical bankruptcy in the United States, 2007: results of a national study.The American journal of medicine, 122 8
N. Summers, U. Dawe, D. Stewart (2000)
A comparison of inpatient and outpatient ASCTBone Marrow Transplantation, 26
J. Rizzo, Georgia Vogelsang, Sharon Krumm, Barbara Frink, Victoria Mock, Eric Bass (1999)
Outpatient-based bone marrow transplantation for hematologic malignancies: cost saving or cost shifting?Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 17 9
ImportanceAdults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) typically remain hospitalized after induction or salvage chemotherapy until blood cell count recovery, with resulting prolonged inpatient stays being a primary driver of health care costs. Pilot studies suggest that outpatient management following chemotherapy might be safe and could reduce costs for these patients. ObjectiveTo compare safety, resource utilization, infections, and costs between adults discharged early following AML or MDS induction or salvage chemotherapy and inpatient controls. DesignNonrandomized, phase 2, single-center study conducted at the University of Washington Medical Center. Over a 43-month period (January 1, 2011, through July 31, 2014), 178 adults receiving intensive AML or MDS chemotherapy were enrolled. After completion of chemotherapy, 107 patients met predesignated medical and logistical criteria for early discharge, while 29 met medical criteria only and served as inpatient controls. InterventionsEarly-discharge patients were released from the hospital at the completion of chemotherapy, and supportive care was provided in the outpatient setting until blood cell count recovery (median, 21 days; range, 2-45 days). Controls received inpatient supportive care (median, 16 days; range, 3-42 days). Main Outcomes and MeasuresWe analyzed differences in early mortality, resource utilization including intensive care unit (ICU) days, transfusions per study day, and use of intravenous (IV) antibiotics per study day), numbers of infections, and total and inpatient charges per study day among early-discharge patients vs controls. ResultsFour of the 107 early-discharge patients and none of the 29 control patients died within 30 days of enrollment (P = .58). Nine early-discharge patients (8%) but no controls required ICU-level care (P = .20). No differences were noted in the median daily number of transfused red blood cell units (0.27 vs 0.29; P = .55) or number of transfused platelet units (0.26 vs 0.29; P = .31). Early-discharge patients had more positive blood cultures (37 [35%] vs 4 [14%]; P = .04) but required fewer IV antibiotic days per study day (0.48 vs 0.71; P = .01). Overall, daily charges among early-discharge patients were significantly lower than for inpatients (median, $3840 vs $5852; P < .001) despite increased charges per inpatient day when readmitted (median, $7405 vs $5852; P < .001). Conclusions and RelevanceEarly discharge following intensive AML or MDS chemotherapy can reduce costs and use of IV antibiotics, but attention should be paid to complications that may occur in the outpatient setting.
JAMA Oncology – American Medical Association
Published: Nov 1, 2015
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.